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Abstract Clavulanic acid (CLAV) inhibits bacterial
b-lactamases and is commonly used to aid antibiotic ther-
apy. Prompted by the initial evidence suggestive of the
potential anticonvulsant and neuroprotective properties of
CLAV, the present study was undertaken to systematically
evaluate its acute effects on seizure thresholds in seizure
tests typically used in primary screening of potential anti-
epileptic drugs (AEDs). In the present study, 6-Hz seizure
threshold, maximal electroshock seizure threshold (MEST)
test, and intravenous pentylenetetrazole (i.v. PTZ) seizure
tests were used to determine anticonvulsant effects of
intraperitoneally (i.p.) administered CLAV in mice. Acute
effects on motor coordination and muscle strength were
assessedinthechimneyandgrip-strengthtests,respectively.
Doses of CLAV studied in the present study were either
comparableorextendedthedosesreportedintheliteratureto
beeffective against kainicacid-inducedconvulsionsinmice
orbehaviorallyactiveinrodentsandmonkeys.CLAVhadno
effectonseizurethresholdsinthe6-Hz(64 ng/kgto1 mg/kg)
and MEST (64 ng/kg to 5 mg/kg) seizure tests. Similarly,
CLAV had no effect on seizure thresholds for i.v. PTZ-
induced myoclonic twitch, clonic convulsions, and tonic
convulsions (64 ng/kg to 5 mg/kg). Finally, CLAV (64 ng/
kg to 5 mg/kg) had no effect on the motor performance and
muscle strength in the chimney and grip-strength tests,
respectively. In summary, CLAV failed to affect seizure
thresholdsinthreeseizuretestsinmice. Althoughtheresults
of the present study do not support further development of
CLAV as an AED, its beneﬁcial effects in chronic epilepsy
models warrant further evaluation owing to its, for example,
potential neuroprotective properties.
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Introduction
With the exception of vigabatrin developed speciﬁcally to
increase the levels of c-aminobutyric acid in the brain
(Lippert et al. 1977) and levetiracetam’s analog briva-
racetam optimized for its activity at a high-afﬁnity ligand
for the synaptic vesicle protein, SV2A (Matagne et al.
2008), this rational, target-based drug discovery and opti-
mization approach has not yet been as successful as the
target-agnostic approach in bringing antiepileptic drugs
(AEDs) to the patients (Gasior and Wiegand 2011). Very
often, compounds effective in pre-clinical seizure tests and
epilepsy models become approved drugs long before their
molecular actions are discovered (e.g., gabapentin and its
activity at a2d proteins) (Gee et al. 1996).
Clavulanic acid (CLAV), a competitive inhibitor of
bacterial b-lactamases which downgrade b-lactam antibi-
otics (Fig. 1), has been used clinically to support antibiotic
therapy for over 30 years (Reading and Cole 1977; Read-
ing et al. 1983; Payne et al. 1994). CLAV readily pene-
trates into the brain (Nakagawa et al. 1994) and has
recently been reported to produce potent anxiolytic effects
with minimal side effects in primates and rodents (Kim
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DOI 10.1007/s00702-011-0662-1et al. 2009). Of note, no signiﬁcant binding of CLAV to
any of the sixty-three primary molecular targets was
detected to support its pharmacological effects in vivo,
including targets typically implicated in mediating anti-
anxiety effects (Kim et al. 2009). Further supporting the
actions of CLAV within the central nervous system, which
translate into measurable in vivo effects were the recent
reports of its stimulatory effect on sexual behavior in rats
(Chan et al. 2009) and beneﬁcial effect on the behavioral
deﬁcit in rodent models of neurodegenerative diseases
(Huh et al. 2010). The latter study also demonstrated efﬁ-
cacy of CLAV against kainic acid-induced convulsions and
lethality in mice (Huh et al. 2010). That study, together
with the reported efﬁcacy of CLAV in a planarian assay of
glutamate- and cocaine-induced convulsions, prompted the
evaluation of CLAV in acute seizure assays with predictive
validity of clinical efﬁcacy and, therefore, recommended
for the primary screen of AED candidates (Smith et al.
2007; Willis et al. 2009; Gasior and Wiegand 2011).
Materials and methods
Animals
Experimentally naive male Albino Swiss mice weighing
25–30 g were obtained from a commercial breeder (Lab-
oratory Animals Breeding, Słaboszo ´w, Poland). The ani-
mals were housed in colony cages under controlled
laboratory conditions (ambient temperature, 22–23C, rel-
ative humidity, 45–55%, 12 h light/dark cycle, lights on at
6:00 a.m.). Chow pellets (Agropol S.J., Motycz, Poland)
and tap water were continuously available. The experi-
mental protocol was approved by the Local Ethics Com-
mittee at the Medical University of Lublin (license number
46/2010), and all the procedures were in strict compliance
with the European Communities Council Directive of 24
November 1986 (86/609/EEC).
Drugs
Clavulanic acid (CLAV, as potassium salt) and pentylen-
etetrazole (PTZ) were used in the present study. All the
compounds were obtained from Sigma-Aldrich (Poznan ´,
Poland). CLAV was dissolved in saline and administered
intraperitoneally (i.p.) in a volume of 10 ml/kg. PTZ was
dissolved in saline and administered intravenously (i.v.).
Pretreatment time for CLAV (60 min) was selected to
correspond to the time to achieve maximal in vivo effect as
conﬁrmed by literature search and in pilot studies.
Psychomotor (6-Hz) seizure threshold test
Psychomotor seizures (6-Hz seizures) were induced by
applying square-wave alternating current (frequency, 6 Hz;
duration, 3 s) via corneal electrodes delivered from a Grass
S48 stimulator (Grass Technologies, West Warwick, RI,
USA). Ocular anesthetic, 1% solution of lidocaine hydro-
chloride (Abbott, Abbott Park, IL, USA), was applied onto
animals’ corneas 1 min before stimulation and 0.9% saline
was used to wet electrodes immediately before testing to
ensure good electrical contact. Each mouse was manually
restrained during stimulation and placed in a Plexiglas
arena (35 cm 9 20 cm 9 14 cm) for behavioral observa-
tion immediately following the stimulation. Convulsions
were characterized by a stunned (ﬁxed) posture, which was
often followed by rearing, forelimb clonus, and twitching
(Barton et al. 2001; Giardina and Gasior 2009). At the end
of the convulsions, the animals resumed normal explor-
atory behavior. Control animals always exhibited more
than 10 s of abnormal behavior whereas treated animals
were considered to be protected if the abnormal behavior
was less than 10 s in duration.
To determine the threshold for 6-Hz seizures, groups of
19–20 mice were stimulated with different current inten-
sities according to an ‘up-and-down’ method (Kimball
et al. 1957; Giardina and Gasior 2009). Each mouse was
stimulated only once at any given current intensity and the
presence or absence of seizure activity was judged as
described above. If the mouse responded with convulsions
(as described above), the next mouse was stimulated with a
current of an intensity 0.06-log step lower than the previous
one. If, however, the mouse did not respond with convul-
sions, the next mouse was stimulated with a current of an
intensity 0.06-log step higher than the previous one. After
all mice from a given treatment group were tested, the
median current strength (CS50 in mA) with corresponding
standard error of the mean (SEM) was calculated as
described elsewhere (Kimball et al. 1957; Giardina and
Gasior 2009). Each CS50 represented a current strength of
the 6-Hz stimulation that was predicted to induce seizures
in 50% of the animals tested.
Maximal electroshock seizure threshold (MEST) test
Generalized tonic-clonic convulsions were induced by
applying a sine-wave alternating current (maximal output
Fig. 1 Chemical structure of CLAV
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123voltage 500 V, 50 Hz for 0.2 s) via corneal electrodes from
a rodent shocker (type 221; Hugo Sachs Elektronik, Frei-
burg, Germany). Sterile saline was used to wet electrodes
immediately before testing to ensure good electrical con-
tact. Mice were manually restrained during stimulation and
immediately after the stimulation. Tonic hind limb exten-
sion (tonus; i.e., the hind limbs of animals out-stretched
180 to the plane of the body axis), which typically
occurred within less than 10 s post stimulation, was taken
as the behavioral endpoint reﬂecting seizure activity
(Lo ¨scher et al. 1991; Giardina and Gasior 2009). The
electrical system of the stimulator was self-adjustable so
that the changes in impedance did not result in the altera-
tions of current intensity (i.e., the system provided constant
current stimulation).
The threshold for maximal electroconvulsions was
determined using the same methodological principles as
described earlier for the ‘‘up-and-down’’ method in the
case of the 6-Hz seizure threshold test (Kimball et al. 1957;
Giardina and Gasior 2009) except for employing different
behavioral endpoint of seizure activity (tonus vs. psycho-
motor seizures) and speciﬁc parameters of electrical stim-
ulation such as the shape (sine vs. square), frequency (50
vs. 6 Hz), and duration (0.2 vs. 3 s) of the stimulating
current between the maximal electroconvulsions and 6-Hz
stimulation, respectively. Seizure threshold in the MEST
test, as described earlier, was expressed as the median
current strength (CS50 in mA) that was predicted to induce
seizures in 50% of the animals tested; corresponding SEM
was calculated for statistical analysis (Kimball et al. 1957;
Giardina and Gasior 2009).
Intravenous PTZ seizure threshold test
Mice were placed in a cylindrical plastic restrainer (12-cm
long, 3-cm inner diameter) with a plunger for restraint. The
lateral tail vein was catheterized with a 2-cm long
27-gauge needle attached to a 25-cm length of polyethyl-
ene tubing PE20RW (Plastics One Inc., Roanoke, VA,
USA). After correct needle placement into the tail vein,
which was veriﬁed by the appearance of blood in the
tubing, the needle was secured gently to the tail using
adhesive tape. The tubing was attached to a 5-ml plastic
syringe containing PTZ solution. The syringe was mounted
on an infusion pump (model Physio 22, Hugo Sachs
Elektronik–Harvard Apparatus GmbH, March-Hugstetten,
Germany). Following catheterization, the mice were
released from the restrainer and placed in a Plexiglas arena
for behavioral observation during the infusion. PTZ
(10 mg/ml) was infused at a rate of 0.2 ml/min. These
infusion parameters were determined to be optimal for the
reliable assessment of behavioral manifestation of i.v.
PTZ-induced seizures. Speciﬁcally, three sequentially-
occurring behavioral endpoints of seizure activity were
used to determine the threshold for seizure induction: (1)
ﬁrst myoclonic twitch (rapid upward ﬂick of rigid tail), (2)
clonus (repeated jerking movements of all four limbs
lasting at least 5 s) with loss of the righting reﬂex (clonic
convulsions, or clonus), and (3) tonic forelimb extension
(tonic convulsions, or tonus). The times between the start
of the infusion and the onset of these endpoints were
recorded and used to calculate seizure thresholds for each
endpoint separately using the following formula: threshold
dose of PTZ (mg/kg) = (PTZ concentration (mg/ml) 9
infusion rate (ml/s) 9 infusion duration (s) 9 1000)/body
weight (g). Seizure threshold was expressed as a mean dose
(±SEM) of PTZ (in mg/kg) needed to produce a given
endpoint as noted above. The infusion was stopped at the
beginning of the tonic convulsions, which was usually
lethal. All surviving animals were euthanized immediately
after the end of the infusion.
Grip test
The acute effect of a range of doses of CLAV on muscular
strength was quantiﬁed by the grip-strength test as descri-
bed elsewhere (Nieoczym et al. 2010). The pretreatment
time for CLAV in the grip-strength test matched that for
seizure tests. The grip-strength apparatus (BioSeb, Cha-
ville, France) comprised a steel wire grid (8 9 8 cm)
connected to an isometric force transducer. The mice were
lifted by the tails so that they could grasp the grid with their
forepaws. The mice were then gently pulled backward by
the tail until they released the grid. The maximal force (in
newtons, N) exerted by the mouse before losing the grip
was recorded. Three consecutive measurements were col-
lected and their means were calculated for each animal.
Then, the mean maximal force (±SEM) for the treatment
group was calculated.
Chimney test
The chimney test was used to assess the acute adverse
effects of a range of doses of CLAV on motor performance
(Boissier et al. 1960). The pretreatment time for CLAV
matched that for seizure tests. In this test, the inability of an
animal to climb backward up through a Plexiglas tube
(3 cm, inner diameter 9 30 cm, length) within 60 s was an
indication of motor impairment. Eight mice per treatment
were subjected to this testing procedure.
Statistical analysis
Threshold values obtained in the i.v. PTZ seizure test are
expressed as group means ±SEM and represent doses of
PTZ (in mg/kg i.v.) necessary to induce myoclonic twitch,
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123clonus, or tonus. An ‘‘up-and-down’’ method was used to
calculate CS50 values, ±SEM, and 95% conﬁdence inter-
vals (CI) in the 6-Hz threshold and MEST tests (Kimball
et al. 1957; Giardina and Gasior 2009). Except for the
categorical data from the chimney test (the Fisher’s exact
test), all the other experimental data from pharmacody-
namic assays were statistically analyzed with either Stu-
dent’s t test or one-way analysis of variance (ANOVA)
followed by Dunnett’s test for speciﬁc post-hoc compari-
sons, where appropriate. Differences were considered sta-
tistically signiﬁcant at p\0.05. All statistical tests were
conducted using GraphPad Prism version 5.0 for Windows
(GraphPad Software, San Diego, CA, USA).
Results
Effects of CLAV on seizure threshold in the 6-Hz test
The control CC50 value for psychomotor seizures was
17.4 ± 1.0 (CI 16.7–18.1) mA in the 6-Hz seizure test.
CLAV (64 ng/kg to 1 mg/kg) had no effect on the seizure
threshold in the 6-Hz test (F(6, 61) = 1.343, p = 0.252,
Fig. 2).
Effects of CLAV on seizure threshold in the MEST test
The effect of CLAV on seizure threshold for generalized
tonus in the MEST test was tested in two separate
experiments at doses ranging from 64 ng/kg to 40 lg/kg
(experiment 1) and from 200 lg to 5 mg/kg (experiment
2). Each experiment included its own well-powered
control group treated with vehicle. Effects of CLAV
versus the matching control group were analyzed sepa-
rately in each experiment in order to avoid creating an
unbalanced number of mice in the control group if both
control groups would have been combined into one
control group.
The control CC50 value for generalized tonus was
7.9 ± 1.0 (CI 7.2–8.7) mA and 9.3 ± 1.0 (CI 8.5–10.2)
mA in experiment 1 and 2, respectively (p = 0.0196;
t test, Fig. 2). CLAV (64 ng/kg to 5 mg/kg) had no effect
on the seizure threshold in the MEST test (experiment
1: F (3, 32) = 1, 492, p = 0.236; experiment 2: F(3, 33) =
0.458, p = 0.714).
Effects of CLAV on seizure threshold in the i.v. PTZ
test
The effect of CLAV on seizure threshold for the onset of
myoclonic twitches, generalized clonus, and generalized
tonus in the i.v. PTZ test (Fig. 3) was tested at doses
ranging from 64 ng/kg to 40 mg/kg (experiment 1) and
from 0.2 to 5 mg/kg (experiment 2). As in the MEST test
(see above), each experiment included its own control
group treated with vehicle and statistical analyses were
performed separately for each experiment.
In vehicle-treated control group, the PTZ thresholds for
the onset of myoclonic twitches were 40.7 ± 1.9 and
40.4 ± 1.3 mg/kg (p[0.05; t test), for generalized clonus
were 52.7 ± 2.6 and 47.7 ± 1.7 mg/kg (p[0.05; t test),
and for generalized tonus were 97.5 ± 6.4 and
100.1 ± 7.7 mg/kg (p[0.05; t test) in experiments 1 and
2, respectively. CLAV had no effect on the threshold for
the onset of myoclonic twitches (experiment 1: F(5,
65) = 0.725, p = 0.202; experiment 2: F(3, 51) = 0.506,
p = 0.680), generalized clonus (experiment 1: F(5,
65) = 2.109, p = 0.075; experiment 2: F(3, 51) = 0.506,
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Fig. 2 Effects of CLAV on seizure thresholds in the 6-Hz and MEST
seizure tests. CLAV was administered at doses ranging from 64 ng/kg
to 5 mg/kg (i.p.) 60 min before seizure testing (open bars); control
groups received saline instead of CLAV (shaded bars). Each group
consisted of 19–20 animals. Data are presented as CC50 values
(±SEM) in mA. Each CC50 value represents current intensity
predicted to produce convulsions in 50% of mice tested at a given
dose of CLAV (Kimball et al. 1957)
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123p = 0.052), and generalized tonus (experiment 1: F(5,
64) = 1.368, p = 0.248; experiment 2: F(3, 51) = 0.209,
p = 0.889) (Fig. 3).
Effects of CLAV on motor performance and muscle
strength in the chimney test and grip strength tests,
respectively
CLAV (64 ng/kg to 5 mg/kg) had no behavioral effect in
the chimney test and grip strength tests (p[0.005; data
not shown).
Discussion
Two studies, one in rats (Huh et al. 2010) and one in
planarians (Rawls et al. 2010), provided the initial evidence
suggestive of the anticonvulsant properties of CLAV and
its potential of becoming a novel anticonvulsant/neuro-
protective agent. CLAV was tested in the present study at
comparable and extended ranges of doses (64 ng/kg to
5 mg/kg, i.p.) demonstrated to be anticonvulsant and neu-
roprotective against seizures and the death of hippocampal
neurons induced by kainic acid in rats (0.01 mg/kg, i.p.),
neuroprotective in a model of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) induced loss of dopaminergic
neurons in mice (0.1 mg/kg, i.p.), or efﬁcacious in behav-
ioral assays in rats (0.001 mg/kg, i.p.; 0.01–1.0 mg/kg,
p.o.), Syrian golden hamsters (10 ng/kg to 1 lg/kg, i.p.), or
cotton-top tamarind monkeys (1 mg/kg, i.p.) (Kim et al.
2009; Chan et al. 2009; Huh et al. 2010). Nevertheless,
CLAV showed no acute anticonvulsant properties in three
seizure tests employed in the present study. Although
speciﬁc pharmacokinetic parameters of CLAV in Albino
Swiss mice have not been studied, the fact that its CNS-
mediated pharmacological effects in vivo were evident
across a variety of species (including a number of rodent
species) would suggest that the failure of CLAV to affect
seizure sensitivity in the present study was not due to its
limited penetration into the CNS in Swiss Albino mice.
Of note, there is not a single approved or under-devel-
opment AED that would not show efﬁcacy in at least one of
the tests employed in the present study (Smith et al. 2007;
Giardina and Gasior 2009; Bialer et al. 2010). Thus, the
results of the present study do not generally support further
consideration of CLAV as an AED. However, the possi-
bility still exists that testing of CLAV after chronic expo-
sure might uncover its anticonvulsant effects as was the
case for some of its behavioral effects (Chan et al. 2009).
Even if not by directly affecting seizure susceptibility,
there still is a potential that the proposed neuroprotective
properties of CLAV (Huh et al. 2010) might beneﬁt, for
example, the treatment of temporal lobe epilepsy. Thus,
further comprehensive testing of CLAV in seizure tests
relevant to speciﬁc molecular mechanisms (e.g., acute
seizure tests employing convulsant agents with speciﬁc
pharmacological actions for further differentiation of
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Fig. 3 Effect of CLAV on the threshold for the onset of ﬁrst
myoclonic twitch, clonus, and tonus in the i.v. PTZ seizure threshold
test in mice. Each group consisted of 10–14 animals. Data are
presented as means (±SEM) in mg/kg of i.v. PTZ necessary to induce
each of the three behavioral endpoints of the i.v. PTZ seizure test
(Giardina and Gasior 2009)
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123anticonvulsant properties) and/or epilepsy models involv-
ing mechanism resulting, among others, from neurode-
generative processes is warranted (Stafstrom and Sutula
2005; Acharya et al. 2008; Gasior and Wiegand 2011;
Lo ¨scher 2011).
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